0

NS1209

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP245063596
CAS245063-59-6
MDL NumberMFCD09955227
Molecular Weight516.57
Description≥98% (HPLC)
SolubilityDMSO: 2 mg/mL, clear
Assay≥98% (HPLC)
Colorwhite to beige
Formpowder
Size5MG, 25MG
Storage Conditions2-8°C
1

Do Traditional Anti-Seizure Drugs Have a Future? A Review of Potential Anti-Seizure Drugs in Clinical Development

Gaetano Zaccara, Dieter Schmidt

Pharmacol Res. 2016 Feb;104:38-48.

PMID: 26689774

1

Effect of Novel AMPA Antagonist, NS1209, on Status Epilepticus. An Experimental Study in Rat

Asla Pitkänen, Claus Mathiesen, Lars Christian B Rønn, Arne Møller, Jari Nissinen

Epilepsy Res. 2007 Apr;74(1):45-54.

PMID: 17289347

1

NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned

Jan M Keppel Hesselink

Drug Dev Res. 2017 Mar;78(2):75-80.

PMID: 28195646

1

The Efficacy of the AMPA Receptor Antagonist NS1209 and Lidocaine in Nerve Injury Pain: A Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study

Lise Gormsen, Nanna B Finnerup, Per M Almqvist, Troels S Jensen

Anesth Analg. 2009 Apr;108(4):1311-9.

PMID: 19299805

1

The Structure of a Mixed GluR2 Ligand-Binding Core Dimer in Complex With (S)-glutamate and the Antagonist (S)-NS1209

Christina Kasper, Darryl S Pickering, Osman Mirza, Lars Olsen, Anders S Kristensen, Jeremy R Greenwood, Tommy Liljefors, Arne Schousboe, Frank Wätjen, Michael Gajhede, Bent W Sigurskjold, Jette S Kastrup

J Mol Biol. 2006 Apr 7;357(4):1184-201.

PMID: 16483599

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode